• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    TriSalus Life Sciences, Inc. - Common Stock (NQ: TLSI )

    5.780 +0.160 (+2.85%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Aug 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 120,682
    Open 5.670
    Bid (Size) 5.680 (1)
    Ask (Size) 5.780 (2)
    Prev. Close 5.620
    Today's Range 5.600 - 5.780
    52wk Range 3.320 - 10.42
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q2 2024
    TLSI stock results show that TriSalus Life Sciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    TriSalus Reports Q2 2024 Financial Results and Business Update
    From TriSalus Life Sciences
    Via Business Wire

    Performance

    YTD
    -29.94%
    -29.94%
    1 Month
    +1.40%
    +1.40%
    3 Month
    -26.84%
    -26.84%
    6 Month
    -36.83%
    -36.83%
    1 Year
    -5.40%
    -5.40%

    More News

    Read More
    TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call
    From TriSalus Life Sciences
    Via Business Wire
    TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation
    From TriSalus Life Sciences
    Via Business Wire
    TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants
    From TriSalus Life Sciences
    Via Business Wire
    TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting
    From TriSalus Life Sciences
    Via Business Wire
    Crude Oil Rises 1%; Verastem Shares Slide
    Via Benzinga
    Exposures Fossil Fuels
    Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Nasdaq Gains 1%; Intuit Shares Plunge
    Via Benzinga
    TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
    From TriSalus Life Sciences
    Via Business Wire
    TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    TriSalus Reports Q1 2024 Financial Results and Business Update
    From TriSalus Life Sciences
    Via Business Wire
    TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors
    From TriSalus Life Sciences
    Via Business Wire
    TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call
    From TriSalus Life Sciences
    Via Business Wire
    TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives
    From TriSalus Life Sciences
    Via Business Wire
    TLSI Stock Earnings: TriSalus Life Sciences Misses EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
    From TriSalus Life Sciences
    Via Business Wire
    Earnings Scheduled For April 1, 2024
    Via Benzinga
    TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting
    From TriSalus Life Sciences
    Via Business Wire
    TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting
    From TriSalus Life Sciences
    Via Business Wire
    TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101
    From TriSalus Life Sciences
    Via Business Wire
    TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors
    From TriSalus Life Sciences
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update
    From TriSalus Life Sciences Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.